Sexual maturity status of female C57BL/6J Mice at different ages. by Yan She (8639796)

Subjects:

Presents the bibliometric search results. by Yan She (8639796)

Subjects:

Flow chart of data screening and analysis. by Yan She (8639796)

Subjects:

S1 Data. Bibliometric analysis. S2 Data. Estrogen level analysis. S3 Data. MicroCT quantification. S4 Data. Markers of bone metabolism. by Yan She (8639796)

Subjects:

Effects of ABZ on the viability of <i>M. corti.</i> by Inés Guarnaschelli (18102211)

“…Viability was not significantly affected for at least 3 days, and then decreased to 38% and 10% for ABZ 1 µM and 10 µM, respectively, by day 10. …”

(A) Hierarchical clustering results of differential proteins in the Model.vs.WKY; (B) Differential protein enrichment bar chart in the Model.vs.WKY; (C) Significantly enriched path... by Xiao Zhang (152326)

Subjects:

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

(a)(b)(c). Relationship between the OHAT-J score for “lips” or “saliva” or “dentures” and the BI at discharge. by Misaki Nakamura (756854)

Minimal data set. by Xiaoxia Liu (294088)

“…In contrast, with a negative Soret coefficient, the growth rate of the spherical crystals increases as the coefficient decreases, and the solute concentration near the interface decreases. …”

Impact of p53 T253I on expression of DNA damage responsive proteins. by Nathaniel C. Holcomb (22793595)

Demographic data of female participants (n = 30). by Vanessa Wellauer (18408477)

Subjects:

Results of physiological parameters. by Vanessa Wellauer (18408477)

Subjects:

Results of recovery parameters. by Vanessa Wellauer (18408477)

Subjects:

The schedule of enrolment, interventions, and assessments of SPIRIT 2013. by Luis Polo-Ferrero (20513578)

Subjects:

Raw data used for statistical analysis. by Vanessa Wellauer (18408477)

Subjects:

Schematic representation of the experimental protocol over time. by Vanessa Wellauer (18408477)

Subjects:

Pairwise comparisons of the intervention effects by time point for physiological parameters. by Vanessa Wellauer (18408477)

Subjects: